Genomic Sequencing Technologies for Medicine: Market Prospects 2011-2021
How will the genomic sequencing market develop this decade? Our new report shows you that industry and market's revenue potential from 2011 to 2021, discussing its prospects.
This report covers technology to support genomics, with an emphasis on pharma R&D. We aim to save you time and aid your decisions through our research, analysis and discussions.
Our new study shows you revenue prospects for genomic technologies at total world, submarket, company and national levels to 2021. Third-generation sequencing platforms can increase throughput and lower costs. We discuss the commercial potential.
You will see how new genomic products and services can change the market. We also discuss prospects for established sequencing technologies. Our revenue forecasting and discussions give answers you need.
You will discover prospects for Roche, Illumina, Complete Genomics, Applied Biosystems, Helicos and other specialists - both established and emerging players. We also discuss activities of Pfizer, J&J, Eli Lilly, GSK, sanofi-aventis, Novartis and other pharma leaders.
We help you to assess the genomic sequencing industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where those technologies are heading, with many sequencing opportunities in oncology and other areas.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies, a technological review and opinions from our survey.
We include 57 tables and charts and a research interview (shown in the accompanying lists). Our study helps you to understand this industry and its potential.
Genomic Sequencing Technologies for Medicine: Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
This report covers technology to support genomics, with an emphasis on pharma R&D. We aim to save you time and aid your decisions through our research, analysis and discussions.
Our new study shows you revenue prospects for genomic technologies at total world, submarket, company and national levels to 2021. Third-generation sequencing platforms can increase throughput and lower costs. We discuss the commercial potential.
You will see how new genomic products and services can change the market. We also discuss prospects for established sequencing technologies. Our revenue forecasting and discussions give answers you need.
You will discover prospects for Roche, Illumina, Complete Genomics, Applied Biosystems, Helicos and other specialists - both established and emerging players. We also discuss activities of Pfizer, J&J, Eli Lilly, GSK, sanofi-aventis, Novartis and other pharma leaders.
We help you to assess the genomic sequencing industry's strengths, weaknesses, trends and revenue opportunities to 2021. You will see where those technologies are heading, with many sequencing opportunities in oncology and other areas.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work - so you won't be left behind
Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies, a technological review and opinions from our survey.
We include 57 tables and charts and a research interview (shown in the accompanying lists). Our study helps you to understand this industry and its potential.
Genomic Sequencing Technologies for Medicine: Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
- You will receive revenue forecasts to 2021 for the world genomic sequencing market and its main components
- You will receive revenue forecasts to 2021 for genomic sequencing technologies in the leading national markets (US, UK, Canada, Germany, France, Spain, Italy, Japan, China and India)
- You will see revenue prospects to 2021 for leading manufacturers, with discussions of market potential and competition
- You will receive an overview of genomics research, showing the importance of sequencing technologies in pharma and healthcare biotechnology
- You will examine features of sequencing technologies, including third-generation sequencing platforms
- You will assess the activities of the pharma industry in genomics research and the importance of public-private partnerships - industry-academia links
- You will investigate strengths, competition and opportunities influencing the genomic sequencing market from 2011 onwards
- You will review driving and restraining forces in the genomic sequencing market
- You will analyse opportunities and challenges for established companies and those seeking to enter the genomic sequencing market
- You will view opinion from our survey.
1. EXECUTIVE SUMMARY
1.1 Review of the Genomic Sequencing Market
1.2 Aims, Scope and Format of Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO GENOMES AND GENOMIC SEQUENCING
2.1 Introduction
2.2 Deoxyribonucleic Acid (DNA)
2.2.1 Introduction to DNA
2.2.2 Genetic Engineering
2.2.3 Forensics
2.2.4 Bioinformatics
2.3 Genomic Sequencing
2.3.1 Introduction
2.3.2 Early Methods of Genomic Sequencing
2.3.3 The History of Genomic Sequencing
2.3.4 High-Throughput Genomic Sequencing
2.3.5 Decline in the Cost of Genomic Sequencing
2.4 Applications for Genomic Research
2.4.1 Rational Design of Pharmaceuticals
2.4.2 Energy and the Environment
2.4.3 Personalised Medicine
2.4.4 Cancer Treatment
2.5 The Impact of Genomics on the Pharmaceutical Industry
2.5.1 Introduction
2.5.2 Pfizer
2.5.3 Johnson & Johnson
2.5.4 GlaxoSmithKline
2.5.5 Sanofi-Aventis
2.5.6 Novartis
2.5.7 AstraZeneca
2.5.8 Roche
2.5.9 Abbott Laboratories
2.5.10 Merck & Co.
2.5.11 Eli Lilly
2.5.12 Bristol-Myers Squibb
3. GENOMIC SEQUENCING TECHNOLOGIES AND LEADING MANUFACTURERS
3.1 Introduction
3.2 Leading Next-Generation Genome Sequencing Technologies, 2011
3.2.1 Pyrosequencing
3.2.2 TruSeq Technology
3.2.3 SOLiD Sequencing
3.2.4 Ion Semiconductor Sequencing
3.2.5 DNA Nanoball Sequencing
3.3 Leading Manufacturers of Genomic Sequencing Technologies, 2011
3.3.1 Roche 454 Life Sciences
3.3.1.1 Genome Sequencer FLX Titanium Series
3.3.2 Illumina
3.3.3 Complete Genomics
3.3.3.1 Complete Genomics' Proprietary Technology
3.3.4 Applied Biosystems
3.3.5 Helicos BioSciences
3.4 The Future of Genomic Sequencing Technologies
3.4.1 Fewer Optics, More Semiconductors
3.4.2 Technology Must Not Out-Pace the Knowledge of Physicians Regarding the Interpretation of Genetic Tests
3.4.3 Will the Majority of Genome Sequencing Machines Be Commercially-Oriented by 2021?
3.4.4 Data May be the Limiting Factor Determining the Future Growth of the Genomic Sequencing Market
4. OVERVIEW OF THE WORLD GENOMIC SEQUENCING MARKET, 2011-2021
4.1 Overview of the Genomic Sequencing Market, 2011-2021
4.2 Effective Cancer Treatment and Prevention is an Important Goal of Genomics Research
4.3 Illumina is the Leading Manufacturer of DNA Sequencing Technologies but Emerging Third-Generation Manufacturers Pose Serious Competition
4.4 Research Continues to be the Leading End-Use Application of Genomic Sequencing Technologies, but Healthcare Will Also be an Important Driver
4.5 The Blockbuster Model of Pharmaceutical R&D Has Serious Deficiencies: Will Slow Change Impede Genomic Medicine?
5. WORLD MARKET FOR GENOMIC SEQUENCING TECHNOLOGIES, 2011-2021
5.1 The Global Market for Genomic Sequencing Technologies, 2009
5.2 Genomic Sequencing Market, 2010-2015
5.2.1 Next-Generation Sequencing Technologies Will Drive Market Growth
5.3 Genomic Sequencing Market, 2016-2021
5.3.1 Genomics in Healthcare Will Provide Challenges and Opportunities
5.4 End-Use Applications of Genomic Sequencing Technologies, 2009-2021
5.4.1 Applications of Genomic Sequencing Technologies, 2009
5.4.2 Applications of Genomic Sequencing Technologies, 2010-2021
5.5 Market Prospects for Genomic Sequencing Platforms According to Instrument Generation, 2009-2021
5.5.1 Second-Generation Sequencing Technologies Show Significant Potential for Market Growth, 2009-2015
5.5.2 Technological Innovation Will Drive Growth in the Third-Generation Sequencing Market, 2016-2021
5.6 Prospects for the Leading Genomic Sequencing Manufacturers, 2011-2021
5.6.1 Leading Manufacturers of Next-Generation Sequencing Platforms, 2011-2021
5.6.2 The Competition is Due to Intensify as Third-Generation Platforms Enter the Genomic Sequencing Market
6. LEADING NATIONAL MARKETS FOR GENOMIC SEQUENCING TECHNOLOGIES, 2011-2021
6.1 Leading National Markets for the Sale of Genomic Sequencing Technologies, 2009
6.2 Forecasts for the Sale of Genomic Sequencing Technologies in the Leading National Markets, 2010-2021
6.2.1 The Genomic Sequencing Market in the USA, 2010-2021
6.2.2 The UK Genomic Sequencing Market, 2010-2021
6.2.3 Other Leading European Markets for Genomic Sequencing Technologies, 2010-2021
6.2.4 The Japanese, Chinese and Indian Genomic Sequencing Markets, 2010-2021
7. ANALYSIS OF FACTORS INFLUENCING THE GENOMIC SEQUENCING MARKET, 2011-2021
7.1 SWOT Analysis of the Genomic Sequencing Market
7.2 Drivers of the Genomic Sequencing Market
7.2.1 Technological Advances in Genome Sequencing
7.2.2 Genomic Sequencing Has a Wide-Range of Applications
7.2.3 Personalised Medicine
7.2.4 Improved Collaborative Ties between Industry and Academia
7.3 Restraints on the Genomic Sequencing Market
7.3.1 Only a Narrow Subset of Proteins is Currently Studied by Structural Biologists
7.3.2 Reductions in Pharmaceutical R&D Spending Will Have an Adverse Effect on the Genomic Sequencing Market
7.3.3 Lack of Clear Guidelines on How to Harness Genomic Sequencing Technologies in the Healthcare Sector
7.4 Outlook for the Genomic Sequencing Market, 2011-2021
7.4.1 Third-Generation Sequencing Platforms Promise Further Reductions in the Costs of Sequencing
7.4.2 Intellectual Property Disputes Will Slow the Advances in Genomic Sequencing Technologies
7.4.3 Data Storage and Handling May Be the Greatest Limiting Factors Determining the Growth of the Genomic Sequencing Market
8. OPINION FROM OUR SURVEY
8.1 Interview with Dr Chas Bountra, Chief Scientist and Head of the Structural Genomics Consortium, University of Oxford, UK
8.1.1 Research at the Structural Genomics Consortium
8.1.2 Genomic Sequencing and Pharmaceutical Drug Discovery
8.1.3 The Challenges Facing the Pharmaceutical Industry
8.1.4 A Model of Drug Discovery Based on Greater Collaboration between Academics and Industry
8.1.5 Genomic Sequencing and Personalised Medicines
8.1.6 Outlook for the Future: Looking Towards 2021
9. OUTLOOK FOR THE GENOMIC SEQUENCING MARKET, 2011-2021
9.1 Will Human Genomics Become Part of Everyday 21st Century Life?
9.2 Whole-Genome Sequencing Will Affect the Healthcare Sector by 2021
9.3 The Clinical Impact of Genomics May be Slower than Expected
9.4 The US and UK Dominate the World Genomic Sequencing Market Now, But Other Countries Will Present Increasing Competition
9.5 Promising Third-Generation Sequencing Technologies and Their Manufacturers
9.5.1 PacBio RS Sequencer
9.5.2 Oxford Nanopore Technologies
9.5.3 The Personal Genome Machine (PGM)
9.5.4 Quantum-Dot Based Sequencing
9.5.5 Helicos Genetic Analysis System
10. CONCLUSIONS
10.1 The Genomic Sequencing Market Will See Rapid Growth from 2011-2021
10.2 China Has the Potential to Become the World's 'Genome Sequencing Factory'
10.3 Data Storage and Analysis Will Be Defining Issues with the Potential to Limit Future Growth in the Genomic Sequencing Market
10.4 Public-Private Partnerships Are a Key to the Resurgence of Pharmaceutical R&D
1.1 Review of the Genomic Sequencing Market
1.2 Aims, Scope and Format of Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO GENOMES AND GENOMIC SEQUENCING
2.1 Introduction
2.2 Deoxyribonucleic Acid (DNA)
2.2.1 Introduction to DNA
2.2.2 Genetic Engineering
2.2.3 Forensics
2.2.4 Bioinformatics
2.3 Genomic Sequencing
2.3.1 Introduction
2.3.2 Early Methods of Genomic Sequencing
2.3.3 The History of Genomic Sequencing
2.3.4 High-Throughput Genomic Sequencing
2.3.5 Decline in the Cost of Genomic Sequencing
2.4 Applications for Genomic Research
2.4.1 Rational Design of Pharmaceuticals
2.4.2 Energy and the Environment
2.4.3 Personalised Medicine
2.4.4 Cancer Treatment
2.5 The Impact of Genomics on the Pharmaceutical Industry
2.5.1 Introduction
2.5.2 Pfizer
2.5.3 Johnson & Johnson
2.5.4 GlaxoSmithKline
2.5.5 Sanofi-Aventis
2.5.6 Novartis
2.5.7 AstraZeneca
2.5.8 Roche
2.5.9 Abbott Laboratories
2.5.10 Merck & Co.
2.5.11 Eli Lilly
2.5.12 Bristol-Myers Squibb
3. GENOMIC SEQUENCING TECHNOLOGIES AND LEADING MANUFACTURERS
3.1 Introduction
3.2 Leading Next-Generation Genome Sequencing Technologies, 2011
3.2.1 Pyrosequencing
3.2.2 TruSeq Technology
3.2.3 SOLiD Sequencing
3.2.4 Ion Semiconductor Sequencing
3.2.5 DNA Nanoball Sequencing
3.3 Leading Manufacturers of Genomic Sequencing Technologies, 2011
3.3.1 Roche 454 Life Sciences
3.3.1.1 Genome Sequencer FLX Titanium Series
3.3.2 Illumina
3.3.3 Complete Genomics
3.3.3.1 Complete Genomics' Proprietary Technology
3.3.4 Applied Biosystems
3.3.5 Helicos BioSciences
3.4 The Future of Genomic Sequencing Technologies
3.4.1 Fewer Optics, More Semiconductors
3.4.2 Technology Must Not Out-Pace the Knowledge of Physicians Regarding the Interpretation of Genetic Tests
3.4.3 Will the Majority of Genome Sequencing Machines Be Commercially-Oriented by 2021?
3.4.4 Data May be the Limiting Factor Determining the Future Growth of the Genomic Sequencing Market
4. OVERVIEW OF THE WORLD GENOMIC SEQUENCING MARKET, 2011-2021
4.1 Overview of the Genomic Sequencing Market, 2011-2021
4.2 Effective Cancer Treatment and Prevention is an Important Goal of Genomics Research
4.3 Illumina is the Leading Manufacturer of DNA Sequencing Technologies but Emerging Third-Generation Manufacturers Pose Serious Competition
4.4 Research Continues to be the Leading End-Use Application of Genomic Sequencing Technologies, but Healthcare Will Also be an Important Driver
4.5 The Blockbuster Model of Pharmaceutical R&D Has Serious Deficiencies: Will Slow Change Impede Genomic Medicine?
5. WORLD MARKET FOR GENOMIC SEQUENCING TECHNOLOGIES, 2011-2021
5.1 The Global Market for Genomic Sequencing Technologies, 2009
5.2 Genomic Sequencing Market, 2010-2015
5.2.1 Next-Generation Sequencing Technologies Will Drive Market Growth
5.3 Genomic Sequencing Market, 2016-2021
5.3.1 Genomics in Healthcare Will Provide Challenges and Opportunities
5.4 End-Use Applications of Genomic Sequencing Technologies, 2009-2021
5.4.1 Applications of Genomic Sequencing Technologies, 2009
5.4.2 Applications of Genomic Sequencing Technologies, 2010-2021
5.5 Market Prospects for Genomic Sequencing Platforms According to Instrument Generation, 2009-2021
5.5.1 Second-Generation Sequencing Technologies Show Significant Potential for Market Growth, 2009-2015
5.5.2 Technological Innovation Will Drive Growth in the Third-Generation Sequencing Market, 2016-2021
5.6 Prospects for the Leading Genomic Sequencing Manufacturers, 2011-2021
5.6.1 Leading Manufacturers of Next-Generation Sequencing Platforms, 2011-2021
5.6.2 The Competition is Due to Intensify as Third-Generation Platforms Enter the Genomic Sequencing Market
6. LEADING NATIONAL MARKETS FOR GENOMIC SEQUENCING TECHNOLOGIES, 2011-2021
6.1 Leading National Markets for the Sale of Genomic Sequencing Technologies, 2009
6.2 Forecasts for the Sale of Genomic Sequencing Technologies in the Leading National Markets, 2010-2021
6.2.1 The Genomic Sequencing Market in the USA, 2010-2021
6.2.2 The UK Genomic Sequencing Market, 2010-2021
6.2.3 Other Leading European Markets for Genomic Sequencing Technologies, 2010-2021
6.2.4 The Japanese, Chinese and Indian Genomic Sequencing Markets, 2010-2021
7. ANALYSIS OF FACTORS INFLUENCING THE GENOMIC SEQUENCING MARKET, 2011-2021
7.1 SWOT Analysis of the Genomic Sequencing Market
7.2 Drivers of the Genomic Sequencing Market
7.2.1 Technological Advances in Genome Sequencing
7.2.2 Genomic Sequencing Has a Wide-Range of Applications
7.2.3 Personalised Medicine
7.2.4 Improved Collaborative Ties between Industry and Academia
7.3 Restraints on the Genomic Sequencing Market
7.3.1 Only a Narrow Subset of Proteins is Currently Studied by Structural Biologists
7.3.2 Reductions in Pharmaceutical R&D Spending Will Have an Adverse Effect on the Genomic Sequencing Market
7.3.3 Lack of Clear Guidelines on How to Harness Genomic Sequencing Technologies in the Healthcare Sector
7.4 Outlook for the Genomic Sequencing Market, 2011-2021
7.4.1 Third-Generation Sequencing Platforms Promise Further Reductions in the Costs of Sequencing
7.4.2 Intellectual Property Disputes Will Slow the Advances in Genomic Sequencing Technologies
7.4.3 Data Storage and Handling May Be the Greatest Limiting Factors Determining the Growth of the Genomic Sequencing Market
8. OPINION FROM OUR SURVEY
8.1 Interview with Dr Chas Bountra, Chief Scientist and Head of the Structural Genomics Consortium, University of Oxford, UK
8.1.1 Research at the Structural Genomics Consortium
8.1.2 Genomic Sequencing and Pharmaceutical Drug Discovery
8.1.3 The Challenges Facing the Pharmaceutical Industry
8.1.4 A Model of Drug Discovery Based on Greater Collaboration between Academics and Industry
8.1.5 Genomic Sequencing and Personalised Medicines
8.1.6 Outlook for the Future: Looking Towards 2021
9. OUTLOOK FOR THE GENOMIC SEQUENCING MARKET, 2011-2021
9.1 Will Human Genomics Become Part of Everyday 21st Century Life?
9.2 Whole-Genome Sequencing Will Affect the Healthcare Sector by 2021
9.3 The Clinical Impact of Genomics May be Slower than Expected
9.4 The US and UK Dominate the World Genomic Sequencing Market Now, But Other Countries Will Present Increasing Competition
9.5 Promising Third-Generation Sequencing Technologies and Their Manufacturers
9.5.1 PacBio RS Sequencer
9.5.2 Oxford Nanopore Technologies
9.5.3 The Personal Genome Machine (PGM)
9.5.4 Quantum-Dot Based Sequencing
9.5.5 Helicos Genetic Analysis System
10. CONCLUSIONS
10.1 The Genomic Sequencing Market Will See Rapid Growth from 2011-2021
10.2 China Has the Potential to Become the World's 'Genome Sequencing Factory'
10.3 Data Storage and Analysis Will Be Defining Issues with the Potential to Limit Future Growth in the Genomic Sequencing Market
10.4 Public-Private Partnerships Are a Key to the Resurgence of Pharmaceutical R&D
LIST OF TABLES
Table 2.1 Average Cost ($m) of Sequencing the Human Genome, 2000-2005
Table 2.2 Average Cost ($m) of Sequencing the Human Genome, 2006-2011
Table 2.3 Average Cost ($) of Sequencing the Human Genome, 2012-2017
Table 2.4 Average Cost ($) of Sequencing the Human Genome, 2018-2021
Table 2.5 Structural Genomics Networks and Activities, 2011
Table 3.1 Costs ($m) and Percentage Shares (%) of the Components Involved in Sequencing a Human Genome, 2007
Table 4.1 US Cancer Research Spending ($m) on Specific Cancer Types, 2009-2011
Table 4.2 Forecast Sales Revenues ($bn) and Market Shares (%) for Illumina DNA Sequencing Platforms, 2009-2015
Table 4.3 Forecast Sales Revenues ($bn) and Market Shares (%) for Illumina DNA Sequencing Platforms, 2016-2021
Table 5.1 World Markets ($bn) for Genomic Sequencing Technologies, 2009-2015
Table 5.2 World Markets ($bn) for Genomic Sequencing Technologies, 2016-2021
Table 5.3 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by End-User Application, 2009-2015
Table 5.4 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by End-User Application, 2016-2021
Table 5.5 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2009-2015
Table 5.6 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2016-2021
Table 5.7 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2009-2015
Table 5.8 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2016-2021
Table 6.1 Sales ($bn) and Market Shares (%) of Genomic Sequencing Technologies in Leading National Markets, 2009
Table 6.2 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2009-2015
Table 6.3 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2016-2021
Table 6.4 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2010-2021
Table 7.1 SWOT Analysis of the Pharmaceutical Genomic Sequencing Market, 2011
Table 9.1 National Distribution of Genomic Sequencing Facilities, 2010
Table 9.2 Some Promising Genomic Sequencing Technologies, 2011
Table 2.1 Average Cost ($m) of Sequencing the Human Genome, 2000-2005
Table 2.2 Average Cost ($m) of Sequencing the Human Genome, 2006-2011
Table 2.3 Average Cost ($) of Sequencing the Human Genome, 2012-2017
Table 2.4 Average Cost ($) of Sequencing the Human Genome, 2018-2021
Table 2.5 Structural Genomics Networks and Activities, 2011
Table 3.1 Costs ($m) and Percentage Shares (%) of the Components Involved in Sequencing a Human Genome, 2007
Table 4.1 US Cancer Research Spending ($m) on Specific Cancer Types, 2009-2011
Table 4.2 Forecast Sales Revenues ($bn) and Market Shares (%) for Illumina DNA Sequencing Platforms, 2009-2015
Table 4.3 Forecast Sales Revenues ($bn) and Market Shares (%) for Illumina DNA Sequencing Platforms, 2016-2021
Table 5.1 World Markets ($bn) for Genomic Sequencing Technologies, 2009-2015
Table 5.2 World Markets ($bn) for Genomic Sequencing Technologies, 2016-2021
Table 5.3 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by End-User Application, 2009-2015
Table 5.4 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by End-User Application, 2016-2021
Table 5.5 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2009-2015
Table 5.6 Market ($bn) Forecasts for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2016-2021
Table 5.7 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2009-2015
Table 5.8 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2016-2021
Table 6.1 Sales ($bn) and Market Shares (%) of Genomic Sequencing Technologies in Leading National Markets, 2009
Table 6.2 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2009-2015
Table 6.3 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2016-2021
Table 6.4 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2010-2021
Table 7.1 SWOT Analysis of the Pharmaceutical Genomic Sequencing Market, 2011
Table 9.1 National Distribution of Genomic Sequencing Facilities, 2010
Table 9.2 Some Promising Genomic Sequencing Technologies, 2011
LIST OF FIGURES
Figure 2.1 Average Cost ($m) of Sequencing the Human Genome, 2000-2005
Figure 2.2 Average Cost ($m) of Sequencing the Human Genome, 2006-2011
Figure 2.3 Average Cost ($) of Sequencing the Human Genome, 2012-2017
Figure 2.4 Average Cost ($) of Sequencing the Human Genome, 2018-2021
Figure 3.1 Percentage Shares (%) of the Costs Involved in Sequencing a Human Genome, 2007
Figure 4.1 US Cancer Research Spending ($m) on Specific Cancer Types, 2010
Figure 4.2 Percentage Shares (%) of US Research Spending on Specific Cancer Types, 2010
Figure 4.3 Percentage Shares (%) of US Research Spending on Specific Cancer Types, 2011
Figure 4.4 Sales Revenues ($bn) for Illumina DNA Sequencing Platforms, 2009-2015
Figure 4.5 Sales Revenues ($bn) for Illumina DNA Sequencing Platforms, 2016-2021
Figure 5.1 World Market ($bn) for Genomic Sequencing Technologies, 2009-2021
Figure 5.2 Market Forecasts ($bn) for the Sale of Genomic Sequencing Technologies by End-User Application, 2009-2021
Figure 5.3 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2010
Figure 5.4 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2015
Figure 5.5 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2021
Figure 5.6 Market Forecasts ($bn) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2009-2021
Figure 5.7 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2011
Figure 5.8 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2016
Figure 5.9 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2021
Figure 5.10 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2009-2021
Figure 5.11 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2010
Figure 5.12 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2015
Figure 5.13 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2021
Figure 6.1 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2009
Figure 6.2 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2010
Figure 6.3 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2015
Figure 6.4 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2021
Figure 6.5 The US Genomic Sequencing Technologies Market ($bn), 2009-2021
Figure 6.6 The UK Genomic Sequencing Technologies Market ($bn), 2009-2021
Figure 6.7 Other Leading European Markets ($bn) for Genomic Sequencing Technologies, 2009-2021
Figure 6.8 The Japanese, Chinese and Indian Genomic Sequencing Markets ($bn), 2009-2021
Figure 9.1 Forecast Revenues ($bn) for the Sale of Genomic Sequencing Technologies Used within the Healthcare Sector, 2009-2021
Figure 9.2 National Distribution (%) of Genomic Sequencing Facilities, 2010
COMPANIES LISTED
454 Life Sciences
Abbott Laboratories
American Association for Cancer Research
American Medical Association
Applied Biosystems
AstraZeneca
AstraZeneca Transgenics & Comparative Genomics Centre
Berkeley Structural Genomics Center
BGI
Brigham & Women's Hospital
Bristol-Myers Squibb
Broad Institute
Celera Genomics
Center for Eukaryotic Structural Genomics
Chinese Academy of Sciences
Complete Genomics
CuraGen
Duke University
DNA Electronics
Eli Lilly
EpiTherapeutics
European Membrane Protein Consortium
ExxonMobil
Food and Drug Administration (US FDA)
Genentech
General Electric (GE)
Genome Analysis Centre
Genomic Science Program
GlaxoSmithKline
Goldman Sachs
Helicos BioSciences
Human Genome Project
IBM
Illumina
Imperial College London
Institute for Systems Biology
Invesco Perpetual
Ion Torrent
IP Group
Joint Center for Structural Genomics
Johnson & Johnson
J. Craig Venter Institute
J.P. Morgan
Lansdowne Partners
Life Technologies
Medco
Medical Council Research Laboratory of Molecular Biology
Medical Research Council (UK)
Membrane Protein Network
Merck & Co.
Microbial Genome Program
Midwest Center for Structural Genomics
Multiple Myeloma Research Foundation
National Cancer Institute (US)
National Center for Biotechnology Information
National Human Genome Research Institute (US)
National Institutes of Health (US)
National Institutes of Health Chemical Genomics Center
New York Structural Genomics Research Consortium
NimbleGen
Northeast Structural Genomics Consortium
Novartis
Ontario Institute for Biotechnology
Ontario Ministry of Research and Innovation
Oxford Nanopore Technologies
Oxford Structural Genomics Consortium
Pacific Biosciences
Paris-Sud Yeast Structural Genomics Project
PerkinElmer
Pfizer
Protein Data Bank
Protein Structure Factory
RIKEN Structural Genomics/Proteomics Institute
Roche
Sage Bionetworks
Sanofi-Aventis
Southeast Collaboratory for Structural Genomics
Stratified Medicines Innovation Platform
Structural Genomics Consortium
Structure 2 Function Project
Swedish Foundation for Strategic Research
Swiss National Center of Competence in Research
Synthetic Genomics
Synthetic Genomics Vaccines
TB Structural Genomics Consortium
Technology Strategy Board (UK)
The Genome Institute at Washington University
The Institute for Genomic Research
Tufts Center for the Study of Drug Development
Translational Genomics Research Institute
UmeŃ… University
University of Ghent
University of Oxford
University of Toronto
US Congress
US Department of Energy
US Government
VisiGen
Wall Street Journal
Washington University
Welcome Trust
Welcome Trust Sanger Institute
World Health Organization
Figure 2.1 Average Cost ($m) of Sequencing the Human Genome, 2000-2005
Figure 2.2 Average Cost ($m) of Sequencing the Human Genome, 2006-2011
Figure 2.3 Average Cost ($) of Sequencing the Human Genome, 2012-2017
Figure 2.4 Average Cost ($) of Sequencing the Human Genome, 2018-2021
Figure 3.1 Percentage Shares (%) of the Costs Involved in Sequencing a Human Genome, 2007
Figure 4.1 US Cancer Research Spending ($m) on Specific Cancer Types, 2010
Figure 4.2 Percentage Shares (%) of US Research Spending on Specific Cancer Types, 2010
Figure 4.3 Percentage Shares (%) of US Research Spending on Specific Cancer Types, 2011
Figure 4.4 Sales Revenues ($bn) for Illumina DNA Sequencing Platforms, 2009-2015
Figure 4.5 Sales Revenues ($bn) for Illumina DNA Sequencing Platforms, 2016-2021
Figure 5.1 World Market ($bn) for Genomic Sequencing Technologies, 2009-2021
Figure 5.2 Market Forecasts ($bn) for the Sale of Genomic Sequencing Technologies by End-User Application, 2009-2021
Figure 5.3 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2010
Figure 5.4 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2015
Figure 5.5 Market Shares (%) for the Sale of Genomic Sequencing Technologies by End-User Application, 2021
Figure 5.6 Market Forecasts ($bn) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2009-2021
Figure 5.7 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2011
Figure 5.8 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2016
Figure 5.9 Market Shares (%) for the Sale of Genomic Sequencing Technologies by Instrument Generation, 2021
Figure 5.10 Revenues ($bn) for the Genomic Sequencing Market by Manufacturer, 2009-2021
Figure 5.11 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2010
Figure 5.12 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2015
Figure 5.13 Market Shares (%) for the Leading Genomic Sequencing Manufacturers, 2021
Figure 6.1 Sales ($bn) of Genomic Sequencing Technologies in Leading National Markets, 2009
Figure 6.2 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2010
Figure 6.3 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2015
Figure 6.4 Leading National Market Shares (%) for the Global Genomic Sequencing Technologies Market, 2021
Figure 6.5 The US Genomic Sequencing Technologies Market ($bn), 2009-2021
Figure 6.6 The UK Genomic Sequencing Technologies Market ($bn), 2009-2021
Figure 6.7 Other Leading European Markets ($bn) for Genomic Sequencing Technologies, 2009-2021
Figure 6.8 The Japanese, Chinese and Indian Genomic Sequencing Markets ($bn), 2009-2021
Figure 9.1 Forecast Revenues ($bn) for the Sale of Genomic Sequencing Technologies Used within the Healthcare Sector, 2009-2021
Figure 9.2 National Distribution (%) of Genomic Sequencing Facilities, 2010
COMPANIES LISTED
454 Life Sciences
Abbott Laboratories
American Association for Cancer Research
American Medical Association
Applied Biosystems
AstraZeneca
AstraZeneca Transgenics & Comparative Genomics Centre
Berkeley Structural Genomics Center
BGI
Brigham & Women's Hospital
Bristol-Myers Squibb
Broad Institute
Celera Genomics
Center for Eukaryotic Structural Genomics
Chinese Academy of Sciences
Complete Genomics
CuraGen
Duke University
DNA Electronics
Eli Lilly
EpiTherapeutics
European Membrane Protein Consortium
ExxonMobil
Food and Drug Administration (US FDA)
Genentech
General Electric (GE)
Genome Analysis Centre
Genomic Science Program
GlaxoSmithKline
Goldman Sachs
Helicos BioSciences
Human Genome Project
IBM
Illumina
Imperial College London
Institute for Systems Biology
Invesco Perpetual
Ion Torrent
IP Group
Joint Center for Structural Genomics
Johnson & Johnson
J. Craig Venter Institute
J.P. Morgan
Lansdowne Partners
Life Technologies
Medco
Medical Council Research Laboratory of Molecular Biology
Medical Research Council (UK)
Membrane Protein Network
Merck & Co.
Microbial Genome Program
Midwest Center for Structural Genomics
Multiple Myeloma Research Foundation
National Cancer Institute (US)
National Center for Biotechnology Information
National Human Genome Research Institute (US)
National Institutes of Health (US)
National Institutes of Health Chemical Genomics Center
New York Structural Genomics Research Consortium
NimbleGen
Northeast Structural Genomics Consortium
Novartis
Ontario Institute for Biotechnology
Ontario Ministry of Research and Innovation
Oxford Nanopore Technologies
Oxford Structural Genomics Consortium
Pacific Biosciences
Paris-Sud Yeast Structural Genomics Project
PerkinElmer
Pfizer
Protein Data Bank
Protein Structure Factory
RIKEN Structural Genomics/Proteomics Institute
Roche
Sage Bionetworks
Sanofi-Aventis
Southeast Collaboratory for Structural Genomics
Stratified Medicines Innovation Platform
Structural Genomics Consortium
Structure 2 Function Project
Swedish Foundation for Strategic Research
Swiss National Center of Competence in Research
Synthetic Genomics
Synthetic Genomics Vaccines
TB Structural Genomics Consortium
Technology Strategy Board (UK)
The Genome Institute at Washington University
The Institute for Genomic Research
Tufts Center for the Study of Drug Development
Translational Genomics Research Institute
UmeŃ… University
University of Ghent
University of Oxford
University of Toronto
US Congress
US Department of Energy
US Government
VisiGen
Wall Street Journal
Washington University
Welcome Trust
Welcome Trust Sanger Institute
World Health Organization
